SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Howe Sound Research | PRODUCT CODE: 2171570

Cover Image

PUBLISHER: Howe Sound Research | PRODUCT CODE: 2171570

Genetic Testing Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook by Application, Technology, Sample Type, Customer, Product and Country - Strategic Analysis of 48 Companies with Executive and Consultant Guides 2027 to 2031

PUBLISHED:
PAGES: 304 Pages; 23 Chapters; 71 Tables; 52 Figures
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 6995
PDF (Five User License)
USD 9995
PDF (Enterprise License)
USD 13995

Add to Cart

Report Overview:

Demand for genetic testing is strong, but the price paid for each test is under more pressure than at any time since the PAMA reforms. This report estimates the global genetic testing market at $28,300 million in 2026, growing 11.6% a year to $49,000 million in 2031 and adding $20,700 million of new annual spending. Oncology is the largest application and adds the most new dollars, oncology and prenatal testing together take more than half of all new spending, NGS rises from 38.5% to 46.5% of the market, and Direct-to-Consumer grows fastest. Genome sequencing grows test by test and will not become routine care for healthy people within the forecast period.

The past year brought CMS's preliminary 2027 lab rates with cuts of about 16% on average, Myriad's cut to its revenue guidance, strong volume growth at Quest and Labcorp, single-draw prenatal panels from Myriad, BillionToOne and Natera, the first additions to the US newborn screening panel under a new decision process, and tighter rules on genetic data in the US and China. The report covers 23 chapters, 71 tables and 52 figures, with forecasts by application, technology, sample type, customer and product for 14 countries and regions, and profiles of 48 companies.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: GENTEST 1026

Table of Contents

List of Tables

List of Figures

1. Executive Summary

  • 1.1 Situation Analysis
  • 1.2 Market Snapshot
  • 1.3 Key Findings
  • 1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

  • 2.1 Scope & Market Definition
  • 2.2 Relationship to Other Howe Sound Research Reports
  • 2.3 Value Basis
  • 2.4 Market Segments
  • 2.5 Geographic Coverage
  • 2.6 Methodology
  • 2.7 Sources
  • 2.8 Author
  • 2.9 Limitations

3. Introduction to Genetic Testing

  • 3.1 What Genetic Tests Find
  • 3.2 Germline and Somatic Testing
  • 3.3 The Main Technologies: PCR, NGS, Cytogenetics and Microarray
  • 3.4 Samples and the Testing Workflow
  • 3.5 A Short History of Genetic Testing
  • 3.6 The Industry and Its Channels

4. The Global Market for Genetic Testing

  • 4.1 Global Market Overview by Country
  • 4.2 Global Market by Application - Overview
  • 4.3 Global Market by Technology - Overview
  • 4.4 Global Market by Sample Type - Overview
  • 4.5 Global Market by Customer - Overview
  • 4.6 Global Market by Product - Overview

5. Newborn Screening

  • 5.1 Market Overview
  • 5.2 The RUSP and the End of the Advisory Committee
  • 5.3 State Programmes and the Dried Blood Spot Workflow
  • 5.4 Suppliers: Revvity and Others
  • 5.5 Genomic Newborn Screening
  • 5.6 International Programmes and Outlook

6. Prenatal, NIPT & Reproductive Testing

  • 6.1 Market Overview
  • 6.2 Cell-free DNA Screening
  • 6.3 Single-gene NIPT, Fetal Antigen Tests and Combined Screens
  • 6.4 Carrier Screening
  • 6.5 Preimplantation Testing and Prenatal Diagnosis
  • 6.6 Companies, Pricing and Outlook

7. Predictive, Carrier & Hereditary Testing

  • 7.1 Market Overview
  • 7.2 Hereditary Cancer
  • 7.3 Cardiovascular, Rare Disease, Predictive and Carrier Testing
  • 7.4 Laboratories and Channels
  • 7.5 Pricing and Payers
  • 7.6 Outlook

8. Oncology Genetic Testing

  • 8.1 The Largest Application
  • 8.2 Tumour Profiling and Companion Diagnostics
  • 8.3 Minimal Residual Disease and Monitoring
  • 8.4 Early Detection in Brief
  • 8.5 Laboratories, Prices and Outlook

9. Direct-to-Consumer & Pharmacogenomics

  • 9.1 Two Applications, One Theme
  • 9.2 Direct-to-Consumer Testing
  • 9.3 Genetic Privacy Laws and the DOJ Data Rule
  • 9.4 Pharmacogenomics
  • 9.5 Outlook

10. Technology Landscape: PCR, NGS, Cytogenetics & Microarray

  • 10.1 Four Technologies, One Market
  • 10.2 PCR: Fast, Cheap and Everywhere
  • 10.3 NGS: The Growth Engine
  • 10.4 Cytogenetics, Microarrays and Optical Genome Mapping
  • 10.5 Other Methods
  • 10.6 Cost, Turnaround and Technology Choice

11. Regulation, Reimbursement & Policy

  • 11.1 Policy Shapes Genetic Testing
  • 11.2 US Reimbursement: The 2027 Medicare Reset
  • 11.3 FDA, LDTs and Newborn Screening Policy
  • 11.4 Europe, China and the Rest of the World
  • 11.5 Genetic Privacy and Data Security
  • 11.6 Policy Outlook

12. Recent Developments

  • 12.1 CMS Publishes Preliminary 2027 Medicare Lab Rates
  • 12.2 Duchenne and MLD Added to the Newborn Screening Panel
  • 12.3 HRSA Funds a National Newborn Screening Workgroup
  • 12.4 Myriad Genetics Cuts 2026 Revenue Guidance
  • 12.5 Myriad Launches the FirstGene Prenatal Screen
  • 12.6 Quest Diagnostics Raises 2026 Guidance on Volume Growth
  • 12.7 European Commission Proposes Simpler MDR and IVDR
  • 12.8 US DOJ Bulk Sensitive Data Rule Fully in Force
  • 12.9 Rhode Island Enacts a Genetic Information Privacy Act
  • 12.10 BillionToOne Launches Fetal Antigen NIPTs

13. Operations, Laboratory Economics & Supply Chain

  • 13.1 From Sample to Report
  • 13.2 Automation and Turnaround
  • 13.3 Cost per Test and Laboratory Economics
  • 13.4 Consolidation and Outreach Laboratory Purchases
  • 13.5 Reagent Supply and Trade Risk
  • 13.6 Staffing and Operational Outlook

14. Competitive Landscape

  • 14.1 Structure of Competition
  • 14.2 Tiers of Players
  • 14.3 Leading Players by Role
  • 14.4 Consolidation and Notable Acquisitions
  • 14.5 Competitive Dynamics
  • 14.6 Outlook for Competition

15. SWOT, Porter's Five Forces & Investment Risk Analysis

  • 15.1 SWOT Analysis
  • 15.2 Porter's Five Forces
  • 15.3 Investment Risk Analysis

16. Strategic Recommendations

  • 16.1 Guidance for Executives, Marketing, Sales and Business Development
  • 16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Application, 2026-2031

  • 17.1 Newborn Screening
  • 17.2 NIPT & Prenatal
  • 17.3 Predictive & Carrier
  • 17.4 Oncology
  • 17.5 Direct-to-Consumer
  • 17.6 Pharmacogenomics
  • 17.7 Other

18. Market Forecast by Technology, 2026-2031

  • 18.1 PCR
  • 18.2 NGS
  • 18.3 Cytogenetics & Microarray
  • 18.4 Other

19. Market Forecast by Sample Type, 2026-2031

  • 19.1 Blood & Plasma
  • 19.2 Saliva & Buccal
  • 19.3 Tissue
  • 19.4 Dried Blood Spot & Other

20. Market Forecast by Customer, 2026-2031

  • 20.1 Academic
  • 20.2 Clinical Labs & Hospitals
  • 20.3 Pharma & Biotech
  • 20.4 Industry & Other

21. Market Forecast by Product, 2026-2031

  • 21.1 Instruments
  • 21.2 Reagents & Kits
  • 21.3 Software
  • 21.4 Services

22. Company Profiles

  • 22.1 23andMe Research Institute (TTAM)
  • 22.2 Abbott Molecular
  • 22.3 Agilent Technologies
  • 22.4 Ambry Genetics (Tempus)
  • 22.5 Ancestry
  • 22.6 ARUP Laboratories
  • 22.7 Baebies
  • 22.8 Baylor Genetics
  • 22.9 Becton, Dickinson and Company (BD)
  • 22.10 BGI Genomics
  • 22.11 BillionToOne
  • 22.12 Bionano
  • 22.13 Bio-Rad Laboratories
  • 22.14 Caris Life Sciences
  • 22.15 Centogene
  • 22.16 Color Health
  • 22.17 Eurofins Scientific
  • 22.18 Exact Sciences (Abbott)
  • 22.19 Foundation Medicine (Roche)
  • 22.20 Fulgent Genetics
  • 22.21 GeneDx
  • 22.22 Genomind
  • 22.23 GRAIL
  • 22.24 Guardant Health
  • 22.25 Helix
  • 22.26 Hologic
  • 22.27 Illumina
  • 22.28 KingMed Diagnostics
  • 22.29 Labcorp (including Invitae assets)
  • 22.30 MGI Tech
  • 22.31 MyHeritage
  • 22.32 Myriad Genetics
  • 22.33 Natera
  • 22.34 Nebula Genomics (DNA Complete)
  • 22.35 NeoGenomics
  • 22.36 Nucleus Genomics
  • 22.37 Oxford Nanopore Technologies
  • 22.38 Pacific Biosciences
  • 22.39 Qiagen
  • 22.40 Quest Diagnostics
  • 22.41 Revvity
  • 22.42 Roche Diagnostics
  • 22.43 Sequencing.com
  • 22.44 Sonic Healthcare
  • 22.45 Tempus AI
  • 22.46 Thermo Fisher Scientific
  • 22.47 Trajan Scientific and Medical (and other dried blood spot suppliers)
  • 22.48 Veracyte

23. Appendix

  • 23.1 Abbreviations
  • 23.2 Developments Archive
  • 23.3 Report Limitations Restated
Product Code: GENTEST 1026

List of Tables

  • Table 1 Key Market Indicators (constant 2026 US$)
  • Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars)
  • Table 3 How This Report Relates to the GENSEQ and GENWHOLE Reports
  • Table 4 Purposes of Genetic Testing and Their Application Segments
  • Table 5 Genetic Testing Technologies, Market Size 2026 and 2031
  • Table 6 Genetic Testing Market by Sample Type, 2026 and 2031
  • Table 7 Milestones in Genetic Testing
  • Table 8 Genetic Testing Market by Customer and by Product, 2026 and 2031
  • Table 9 Global Market by Country
  • Table 10 Global Market by Application
  • Table 11 Global Market by Technology
  • Table 12 Global Market by Sample Type
  • Table 13 Global Market by Customer
  • Table 14 Global Market by Product
  • Table 15 Newborn Screening and Dried Blood Spot Markets, 2026 and 2031
  • Table 16 US Newborn Screening Policy Timeline
  • Table 17 Newborn Screening Methods on the Dried Blood Spot
  • Table 18 Selected Newborn Screening Suppliers
  • Table 19 Newborn Screening Programmes by Region
  • Table 20 Prenatal and Reproductive Genetic Tests
  • Table 21 Leading Companies in Prenatal and Reproductive Testing
  • Table 22 Predictive & Carrier Testing Market, 2026 and 2031
  • Table 23 Leading Providers of Predictive, Carrier and Hereditary Testing
  • Table 24 Factors Affecting Volume and Price in Predictive & Carrier Testing
  • Table 25 Oncology Genetic Testing Market, 2026 and 2031
  • Table 26 Leading Oncology Genetic Testing Providers, 2026
  • Table 27 Direct-to-Consumer and Pharmacogenomics Markets, 2026 and 2031
  • Table 28 Selected Direct-to-Consumer Genetic Tests
  • Table 29 Selected Genetic Privacy Measures Affecting Genetic Testing, 2025-2026
  • Table 30 Genetic Testing Market by Technology, 2026 and 2031
  • Table 31 Indicative Cost and Turnaround of Main Genetic Test Types, 2026
  • Table 32 Key Regulatory, Reimbursement and Policy Factors, October 2026
  • Table 33 Main Features of the Preliminary 2027 Medicare Laboratory Rates
  • Table 34 Recent Developments at a Glance
  • Table 35 Genetic Testing Market by Sample Type, 2026 and 2031
  • Table 36 Main Cost Elements in a Genetic Testing Laboratory
  • Table 37 Selected Hospital Laboratory Transactions by Labcorp and Quest, December 2024 to January 2026
  • Table 38 Competitive Structure by Application
  • Table 39 Tiers of Genetic Testing Competitors
  • Table 40 Selected Genetic Testing Laboratories
  • Table 41 Selected Genetic Testing Suppliers
  • Table 42 Notable Acquisitions in Genetic Testing, 2024-2026
  • Table 43 SWOT Analysis - Strengths and Weaknesses
  • Table 44 SWOT Analysis - Opportunities and Threats
  • Table 45 Porter's Five Forces Ratings
  • Table 46 Investment Risk Matrix
  • Table 47 Selected Growth Opportunities
  • Table 48 Newborn Screening by Country
  • Table 49 NIPT & Prenatal by Country
  • Table 50 Predictive & Carrier by Country
  • Table 51 Oncology by Country
  • Table 52 Direct-to-Consumer by Country
  • Table 53 Pharmacogenomics by Country
  • Table 54 Other by Country
  • Table 55 PCR by Country
  • Table 56 NGS by Country
  • Table 57 Cytogenetics & Microarray by Country
  • Table 58 Other by Country
  • Table 59 Blood & Plasma by Country
  • Table 60 Saliva & Buccal by Country
  • Table 61 Tissue by Country
  • Table 62 Dried Blood Spot & Other by Country
  • Table 63 Academic by Country
  • Table 64 Clinical Labs & Hospitals by Country
  • Table 65 Pharma & Biotech by Country
  • Table 66 Industry & Other by Country
  • Table 67 Instruments by Country
  • Table 68 Reagents & Kits by Country
  • Table 69 Software by Country
  • Table 70 Services by Country
  • Table 71 Developments Archive: Items from 2024-2025 in the Previous Edition

List of Figures

  • Figure 1 Key Graphic - NGS Takes Over: Genetic Testing Market by Technology, 2026 vs 2031 17
  • Figure 2 DNA Strands and Chromosomes
  • Figure 3 Karyogram of Human Chromosomes
  • Figure 4 Global Market Pareto Chart
  • Figure 5 Global Market by Application - Base vs. Final
  • Figure 6 Global Market by Application Base Year
  • Figure 7 Global Market by Application End Year
  • Figure 8 Application Share by Year
  • Figure 9 Application Segments Growth
  • Figure 10 Global Market by Technology - Base vs. Final
  • Figure 11 Global Market by Technology Base Year
  • Figure 12 Global Market by Technology End Year
  • Figure 13 Technology Share by Year
  • Figure 14 Technology Segments Growth
  • Figure 15 Global Market by Sample Type - Base vs. Final
  • Figure 16 Global Market by Sample Type Base Year
  • Figure 17 Global Market by Sample Type End Year
  • Figure 18 Sample Type Share by Year
  • Figure 19 Sample Type Segments Growth
  • Figure 20 Global Market by Customer - Base vs. Final
  • Figure 21 Global Market by Customer Base Year
  • Figure 22 Global Market by Customer End Year
  • Figure 23 Customer Share by Year
  • Figure 24 Customer Segments Growth
  • Figure 25 Global Market by Product - Base vs. Final
  • Figure 26 Global Market by Product Base Year
  • Figure 27 Global Market by Product End Year
  • Figure 28 Product Share by Year
  • Figure 29 Product Segments Growth
  • Figure 30 Newborn Screening Growth
  • Figure 31 NIPT & Prenatal Growth
  • Figure 32 Predictive & Carrier Growth
  • Figure 33 Oncology Growth
  • Figure 34 Direct-to-Consumer Growth
  • Figure 35 Pharmacogenomics Growth
  • Figure 36 Other Growth
  • Figure 37 PCR Growth
  • Figure 38 NGS Growth
  • Figure 39 Cytogenetics & Microarray Growth
  • Figure 40 Other Growth
  • Figure 41 Blood & Plasma Growth
  • Figure 42 Saliva & Buccal Growth
  • Figure 43 Tissue Growth
  • Figure 44 Dried Blood Spot & Other Growth
  • Figure 45 Academic Growth
  • Figure 46 Clinical Labs & Hospitals Growth
  • Figure 47 Pharma & Biotech Growth
  • Figure 48 Industry & Other Growth
  • Figure 49 Instruments Growth
  • Figure 50 Reagents & Kits Growth
  • Figure 51 Software Growth
  • Figure 52 Services Growth
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!